The pharmaceutical company “Darnitsa” is planning to significantly reduce the time for the release of new drugs. This was stated by the chairman of the board of directors of Darnitsa - Dmytro Shymkiv. According to him, the increase in the range of products and production rates has become possible due to the use of modern IT technologies in the development, testing and production of medicines.
According to information from the management of Darnitsa Group, by the end of 2021 the plant is planning to produce over 25 pharmaceutical brands. At the same time, the total number of commodity items will be more than fifty, and every fourth product from this list will be delivered to pharmacy chains 4 months earlier than the planned schedule. This increase in production turnover has been facilitated by the systematic introduction of innovative methods and technologies into the work of the company. Dmytro Shymkiv has repeatedly stated this in his interviews and public speeches.
Timely, regular and large investments in the amount of about UAH 100 million and the early start of digital transformation of production processes had a positive impact on the speed of registration and making changes in medicinal product dossiers. Due to this, it was also possible to minimize the risks provoked by quarantine restrictions. The comprehensive modernization allowed the “Darnitsa” company to register a new product every 2 weeks during 2020 and re-register its products on a weekly basis.
Speaking about the importance and necessity of digital transformations, Dmytro Shymkiv said that recently there has been a strong tendency to strengthen the role of the IT industry in the healthcare system. The symbiosis of high technologies and medicine will continue to develop and strengthen in the future. This will allow not only to minimize the time of development, research and production of pharmaceutical products, but also to significantly increase the level of medicine in all areas from prevention and diagnostics to therapy. So, for example, the employees of “Darnitsa” are already closely engaged in the study of genetic data. These studies will help to improve the accuracy of predicting potential human diseases. In addition, the pharmaceutical concern completely switched to electronic monitoring of drug administration and began using digital master files (eTMF) in the process of clinical trials.